EGFR
The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase of the ErbB family. Four members of the ErbB family have been identified; EGFR (ErbB1, HER1), ErbB2 (HER2), ErbB3 (HER3) and ErbB4 (HER4). EGFR signaling drives many cellular responses.
Inhibitors |
|
|---|---|
| Cat No | Product Name / Activity |
| 5318 | AEE 788 |
| Potent EGFR and VEGFR inhibitor | |
| 1276 | AG 1478 hydrochloride |
| Highly potent EGFR-kinase inhibitor | |
| 0493 | AG 18 |
| EGFR/PDGFR-kinase inhibitor | |
| 0414 | AG 490 |
| EGFR-kinase inhibitor. Also JAK2, JAK3 inhibitor | |
| 0619 | AG 494 |
| Potent EGFR-kinase inhibitor | |
| 0618 | AG 555 |
| Potent EGFR-kinase inhibitor | |
| 0616 | AG 556 |
| EGFR-kinase inhibitor | |
| 1555 | AG 825 |
| Selective ErbB2 inhibitor | |
| 2617 | AG 879 |
| ErbB2 inhibitor | |
| 0497 | AG 99 |
| EGFR-kinase inhibitor | |
| 4397 | AV 412 |
| Potent inhibitor of EGFR, ErbB2 and Abl receptor tyrosine kinases | |
| 2417 | BIBU 1361 dihydrochloride |
| Selective inhibitor of EGFR-kinase | |
| 2416 | BIBX 1382 dihydrochloride |
| Highly selective EGFR-kinase inhibitor | |
| 5022 | BMS 599626 dihydrochloride |
| Potent, selective EGFR and ErbB2 inhibitor | |
| 5916 | Canertinib dihydrochloride |
| Potent EGFR kinase inhibitor | |
| 3360 | CGP 52411 |
| EGFR inhibitor. Also inhibits Aβ42 fibril formation | |
| 5973 | CP 724714 |
| Potent and selective ErbB2 inhibitor | |
| 6231 | Dacomitinib |
| Potent irreversible pan ErbB inhibitor | |
| 4502 | DIM |
| Inhibits EGFR activation; also induces apoptosis | |
| 1110 | Genistein |
| EGFR kinase inhibitor. Also estrogen and PPARγ ligand | |
| 2239 | GW 583340 dihydrochloride |
| Potent dual EGFR/ErbB2 inhibitor; orally active | |
| 3580 | HKI 357 |
| Dual irreversible inhibitor of ErbB2 and EGFR | |
| 3000 | Iressa |
| Orally active, selective EGFR inhibitor | |
| 3352 | JNJ 28871063 hydrochloride |
| Potent ErbB receptor family inhibitor | |
| 1331 | Lavendustin A |
| EGFR, p60c-src inhibitor | |
| 0577 | Methyl 2,5-dihydroxycinnamate |
| EGFR-kinase inhibitor | |
| 1037 | PD 153035 hydrochloride |
| EGFR-kinase inhibitor | |
| 2615 | PD 158780 |
| Potent ErbB receptor family inhibitor | |
| 5939 | PF 6274484 |
| High affinity and potent covalent EGFR kinase inhibitor | |
| 4941 | PKI 166 hydrochloride |
| Potent EGFR-kinase inhibitor | |
| 2794 | PP 3 |
| EGFR-kinase inhibitor. Also Src kinase negative control | |
| 3599 | TAK 165 |
| Potent and selective ErbB2 inhibitor | |
| 0578 | Tyrphostin B44, (-) enantiomer |
| EGFR-kinase inhibitor | |
| 0579 | Tyrphostin B44, (+) enantiomer |
| EGFR-kinase inhibitor | |
| 3115 | WHI-P 154 |
| Potent EGFR inhibitor. Also inhibits JAK3 | |
The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase of the ErbB family. Four members of the ErbB family have been identified: EGFR (ErbB1, HER1), ErbB2 (HER2), ErbB3 (HER3) and ErbB4 (HER4).
EGFR signaling is initiated by ligand binding to the extracellular ligand binding domain. This initiates receptor homo-/heterodimerization and autophosphorylation by the intracellular kinase domain, resulting in receptor activation. Following activation, phosphorylation of cytoplasmic substrates occurs and a signaling cascade is initiated that drives many cellular responses, including changes in gene expression, cytoskeletal rearrangement, decreased apoptosis and increased cell proliferation.
External sources of pharmacological information for EGFR :
Literature for EGFR
Tocris offers the following scientific literature for EGFR to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Cancer Research Product Guide
A collection of over 750 products for cancer research, the guide includes research tools for the study of:
- Cancer Metabolism
- Epigenetics in Cancer
- Receptor Signaling
- Cell Cycle and DNA Damage Repair
- Angiogenesis
- Invasion and Metastasis
Kinases Product Listing
A collection of over 400 products for kinase research, the listing includes inhibitors of:
- Receptor Tyrosine Kinases
- Protein Kinases A, C, D and G
- PI-3 Kinase, Akt and mTOR
- MAPK Signaling
- Receptor Serine/Threonine Kinases
Angiogenesis in Cancer Poster
Adapted from the 2015 Cancer Product Guide, Edition 3, this poster summarizes the pathogenesis of angiogenesis in cancer, as well as some of the main angiogenesis therapeutic targets.
Schizophrenia Poster
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.
EGF Receptor Gene Data
| Gene | Species | Gene Symbol | Gene Accession No. | Protein Accession No. |
|---|---|---|---|---|
| EGFR | Human | EGFR | NM_005228 | P00533 |
| Mouse | Egfr | NM_207655 | Q01279 | |
| Rat | Egfr | NM_031507 | Q62954 | |
| ErbB2 | Human | ERBB2 | NM_001005862 | P04626 |
| Mouse | Erbb2 | NM_001003817 | P70424 | |
| Rat | Erbb2 | NM_017003 | P06494 | |
| ErbB3 | Human | ERBB3 | NM_001005915 | P21860 |
| Mouse | Erbb3 | NM_010153 | Q61526 | |
| Rat | Erbb3 | NM_017218 | Q62799 | |
| ErbB4 | Human | ERBB4 | NM_001042599 | Q15303 |
| Mouse | Erbb4 | NM_010154 | Q61527 | |
| Rat | Erbb4 | NM_021687 | Q62956 |
Our Cancer Research Guide highlights over 750 products for cancer research.
Request copyDownload PDF
Our Kinase listing highlights over 400 products for kinase research.
Request copyDownload PDFTaken from the Cancer Product Guide Edition 3
Our Angiogenesis in Cancer poster summarizes the pathogenesis of angiogenesis in cancer, as well as some of the main angiogenesis therapeutic targets.
Request copyDownload PDFWritten by Justin M. Saunders and Javier González-Maeso
Our Schizophrenia poster higlights the targets and pathways representing the most promising strategies to pursue for novel drug development.
Request copyDownload PDF